Modulation of body temperature and locomotive activity by rosiglitazone and pioglitazone treatment during adjuvant-induced arthritis. Animals were treated daily with 3 or 10 mg/kg of rosiglitazone (ROSI) or 3, 10 or 30 mg/kg of pioglitazone (PIO) by oral administration. Effect on (a) mean nocturnal body temperature, (b) primary inflammation, expressed as area under the time curve (AUC) of body temperature from day 0 to day 3 after sensitization, (c) secondary immunological inflammation, expressed as area under the time curve (AUC) of body temperature from day 4 to day 17 after sensitization, and (d) mean locomotive activity. Data are expressed as means ± SEM for at least five animals (ROSI 3, PIO 3 and 10) or 10 animals (normal controls, adjuvant-induced arthritis (AIA) controls, ROSI 10 and PIO 30). *, P < 0.05 compared with normal controls; #, P < 0.05 compared with AIA controls (ANOVA and Fisher's PLSD post-hoc test). Dn, day n; Nn, night n.
Koufany et al. Arthritis Research & Therapy 2008 10:R6 doi:10.1186/ar2354